Navigation Links
Celebrex Plus Lipitor Could Fight Prostate Cancer
Date:4/14/2008

Combining painkiller with statin slows tumor progression, mouse study suggests

MONDAY, April 14 (HealthDay News) -- Two widely used drugs -- one lowers cholesterol and one is an anti-inflammatory -- may be useful in controlling prostate cancer.

New research being presented at the American Association for Cancer Research annual meeting in San Diego finds that the painkiller Celebrex and the statin Lipitor, when used together or alone, can stop early prostate cancer before it becomes deadly.

The study was conducted in mice so the idea isn't yet ready for clinical use, but experts said these preliminary results did look promising.

"They need to come up with the molecular mechanics and then take it back to clinical trials," said Dr. K. Scott Coffield, a professor of surgery at Texas A&M Health Science Center College of Medicine and a urologist-oncologist at Scott & White. "It's early but it's interesting and that's wonderful."

"It's very intriguing and it gives some clinical data, but it's not enough to start recommending these medications for people who don't need them for other reasons," added Dr. Ronald D. Ennis, director of radiation oncology at St. Luke's Roosevelt Hospital, Continuum Cancer Centers, in New York City.

Prostate cancer is the second-leading cancer killer in men in the United States. In the early stages, prostate tumors depend on androgen (male) hormones such as testosterone to grow. As such, early treatment typically involves interfering with these hormones but these therapies eventually lose their effectiveness. Tumors that are dependent on androgen are typically less aggressive than later tumors that don't rely on androgen.

Epidemiological studies have suggested that statins (such as Lipitor) and nonsteroidal anti-inflammatory drugs (such as Celebrex) may be able to stop the progression from an early cancer to a later, more aggressive malignancy.

This study aimed to delay the progression of androgen-dependent tumors to androgen-independent tumors, thus allowing doctors more time to administer anti-hormone therapy. Anti-androgen therapy is less toxic than many other cancer therapies, as are Lipitor and Celebrex.

"Comparing complications for many anti-cancer treatments, these drugs generally would be very safe," Ennis said. (Celebrex, a cox-2 inhibitor, is the only drug in this class still on the market in the United States; two others, Vioxx and Bextra, were withdrawn because of safety issues).

In the study, the investigators first cultured prostate tumors in mice, then added in either Lipitor or Celebrex, and then the combination of the two drugs.

All three approaches inhibited cancer growth. Interestingly, however, the combination of Lipitor and Celebrex at lower doses than when given individually resulted in a greater effect, the team found.

"It had a pretty substantial effect with this combination," said study senior author Allan Conney, director of the Susan Lehman Komen Laboratory for Cancer Research at the Ernest Mario School of Pharmacy of Rutgers University, in New Brunswick, N.J.

"We're hoping that this can be extrapolated to humans," Conney added. "There's a need to do a clinical trial on this combination of Lipitor and Celebrex to see if it can prolong the time that it takes to convert the androgen-dependent tumors to androgen-independent tumors, which are the more severe kind."

As of now, it's unclear why Lipitor and Celebrex are having this effect on prostate tumors.

Ennis doubted it was a cholesterol issue. "Statins as a group must have another effect beyond lowering cholesterol," he said. "They're known to have some anti-inflammatory effects but what they're doing to cancer isn't known yet. Once we figure that out, we may be able to develop better drugs that do the same thing."

"That's very exciting but not yet enough to start prescribing this for prostate cancer," Ennis added.

More information

There's more on prostate cancer at the American Cancer Society.



SOURCES: Allan Conney, Ph.D., Garbe professor, cancer and leukemia research, and director, Susan Lehman Komen Laboratory for Cancer Research, Ernest Mario School of Pharmacy, Rutgers University, New Brunswick, N.J.; Ronald D. Ennis, M.D., director, radiation oncology, St. Luke's Roosevelt Hospital, Continuum Cancer Centers, New York City; K. Scott Coffield, M.D., professor, surgery, Texas A&M Health Science Center College of Medicine and urologist-oncologist, Scott&White


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Celebrex-Lipitor combo may halt prostate cancer
2. Statement of Robert Jarvik, MD, President and CEO of Jarvik Heart, Inc. Regarding the Lipitor DTC Advertisements
3. Study provides hope that some transplant patients could live free of antirejection drugs
4. Study provides hope that some transplant patients could live free of anti-rejection drugs
5. HIV denialists spread misinformation online -- consequences could be deadly; and more
6. Virus Could Help Drive Obesity
7. Discovery of sugar sensor in intestine could benefit diabetes
8. Cranberry Could Juice Up Ovarian Cancer Treatment
9. Treating Diabetes During Pregnancy Could Lead to Thinner Kids
10. High-risk behaviors could lead to HIV epidemic in Afghanistan
11. Chinas 1-child policy could backfire on its elderly
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Celebrex Plus Lipitor Could Fight Prostate Cancer
(Date:10/13/2017)... ... , ... Apple Rehab Shelton Lakes , which specializes in the delivery ... as part of a disaster drill on October 3rd. , Apple Rehab participated with ... Manager, as well as the Connecticut Long Term Care Mutual Aid Plan (LTC-MAP). ...
(Date:10/13/2017)... Texas (PRWEB) , ... October 13, 2017 , ... Yisrayl ... this week that explains one of the most popular and least understood books in ... like cryptic and puzzling descriptions that have baffled scholars for centuries. Many have tossed ...
(Date:10/12/2017)... ... October 12, 2017 , ... First Healthcare Compliance (FHC), ... will showcase a range of technology and learning solutions at the 68th Annual ... Expo to be held October 14–18, 2017 at the Mandalay Bay Resort in ...
(Date:10/12/2017)... ... October 12, 2017 , ... The American College of Medical ... Friedman, PhD, FACMI, during the Opening Session of AMIA’s Annual Symposium in Washington, D.C. ... honor of Morris F. Collen, a pioneer in the field of medical informatics, this ...
(Date:10/12/2017)... ... , ... Leading pediatric oncology experts at Children’s National Health System ... of the International Society of Paediatric Oncology (SIOP) Oct. 12-15. Chaired by ... Blood Disorders at Children’s National, and Stephen P. Hunger, M.D., Chief of the ...
Breaking Medicine News(10 mins):
(Date:10/4/2017)... Oct. 4, 2017  South Korean-based healthcare product Development ... aide "cprCUBE" on Kickstarter. The device will educate the ... arrests with better efficiency compared to the dated and ... feedback on efficacy of the compression for a more ... a goal to raise $5,000. ...
(Date:10/2/2017)... 2, 2017  AllianceRx Walgreens Prime, the combined central ... and pharmacy benefit manager Prime Therapeutics LLC (Prime), today ... included the unveiling of new signage at its headquarters ... as at a few other company-owned facilities across the ... patients, some of whom will begin to see the ...
(Date:9/27/2017)...  Commended for their devotion to personalized service, SMP Pharmacy ... one in the South Florida Business Journal,s 50 Fastest-Growing Companies, ... list, the national specialty pharmacy has found its niche.  To ... soon be honored by SFBJ as the 2017 Power Leader ... to receive his award in October, Bardisa said of the ...
Breaking Medicine Technology: